Vol. 5 No. 10 (2025)
Reimbursement Recommendations

Venetoclax (Venclexta)

decorative image of the issue cover

Published October 1, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Venclexta, in combination with ibrutinib (Venclexta plus ibrutinib), be reimbursed by public drug plans for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) if certain conditions are met.
  • Venclexta should only be covered for adults who are in relatively good health and have already tried at least 1 other treatment for this disease.
  • Venclexta should only be reimbursed if it is prescribed by clinicians with expertise in managing MCL and monitoring therapy, and the cost of Venclexta is reduced.